Pan LF, Niu ZQ, Ren S, Pei HH, Gao YX, Feng H, Sun JL, Zhang ZL. Could extracellular vesicles derived from mesenchymal stem cells be a potential therapy for acute pancreatitis-induced cardiac injury? World J Stem Cells 2023; 15(7): 654-664 [PMID: 37545754 DOI: 10.4252/wjsc.v15.i7.654]
Corresponding Author of This Article
Long-Fei Pan, MD, Associate Chief Physician, Associate Professor, Emergency Department, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi’an 710004, Shaanxi Province, China. panlonf@yeah.net
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Long-Fei Pan, Ze-Qun Niu, Hong-Hong Pei, Yan-Xia Gao, Hui Feng, Jiang-Li Sun, Zheng-Liang Zhang, Emergency Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Song Ren, Department of Geriatric Digestive Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an 710004, Shaanxi Province, China
Author contributions: Pan LF designed, reviewed, and was responsible for the manuscript; Pan LF and Niu ZQ wrote and revised the manuscript; Niu ZQ, Ren S, Pei HH, Gao YX, Feng H, Sun JL, and Zhang ZL conducted literature searches; and all authors have read and approve the final manuscript.
Supported bythe Natural Science Basic Research Program of Shaanxi Province, China, No. 2021JM-284; Health Research Projects of Shaanxi Province, China, No. 2021A010; and Science and Technology Planning Project of Xi’an, China, No. 22YXYJ0111.
Conflict-of-interest statement: The authors declare that the research was conducted without any commercial or financial relationships that could be perceived as potential conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Long-Fei Pan, MD, Associate Chief Physician, Associate Professor, Emergency Department, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157 Xiwu Road, Xincheng District, Xi’an 710004, Shaanxi Province, China. panlonf@yeah.net
Received: April 27, 2023 Peer-review started: April 27, 2023 First decision: May 19, 2023 Revised: June 11, 2023 Accepted: June 27, 2023 Article in press: June 27, 2023 Published online: July 26, 2023 Processing time: 88 Days and 12.3 Hours
Abstract
Acute pancreatitis (AP) often leads to a high incidence of cardiac injury, posing significant challenges in the treatment of severe AP and contributing to increased mortality rates. Mesenchymal stem cells (MSCs) release bioactive molecules that participate in various inflammatory diseases. Similarly, extracellular vesicles (EVs) secreted by MSCs have garnered extensive attention due to their comparable anti-inflammatory effects to MSCs and their potential to avoid risks associated with cell transplantation. Recently, the therapeutic potential of MSCs-EVs in various inflammatory diseases, including sepsis and AP, has gained increasing recognition. Although preclinical research on the utilization of MSCs-EVs in AP-induced cardiac injury is limited, several studies have demonstrated the positive effects of MSCs-EVs in regulating inflammation and immunity in sepsis-induced cardiac injury and cardiovascular diseases. Furthermore, clinical studies have been conducted on the therapeutic application of MSCs-EVs for some other diseases, wherein the contents of these EVs could be deliberately modified through prior modulation of MSCs. Consequently, we hypothesize that MSCs-EVs hold promise as a potential therapy for AP-induced cardiac injury. This paper aims to discuss this topic. However, additional research is essential to comprehensively elucidate the underlying mechanisms of MSCs-EVs in treating AP-induced cardiac injury, as well as to ascertain their safety and efficacy.
Core Tip: Acute pancreatitis (AP) often causes cardiac injury, leading to poor prognosis. Mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) possess anti-inflammatory properties and have been studied as a potential therapy for inflammatory diseases. Although preclinical studies on the use of MSCs-EVs for AP-induced cardiac injury are lacking, research has demonstrated their positive effects in various inflammatory diseases such as sepsis-induced cardiac injury and cardiovascular diseases. Therefore, MSCs-EVs may represent a promising strategy for treating AP-induced cardiac injury.
